81 related articles for article (PubMed ID: 24161159)
1. Prescribing patterns of duloxetine in France: a prescription assessment study in real-world conditions.
Augendre-Ferrante B; Picard H; Evans D; Arkoub H; Pamulapati S; Perrot S; Valensi P; Rouillon F
Int J Clin Pharmacol Ther; 2014 Jan; 52(1):1-7. PubMed ID: 24161159
[TBL] [Abstract][Full Text] [Related]
2. Dosing patterns for duloxetine and predictors of high-dose prescriptions in patients with major depressive disorder: analysis from a United States third-party payer perspective.
Liu X; Cui Z; Niu L; Faries DE; Ball T; Johnstone B
Clin Ther; 2011 Nov; 33(11):1726-38. PubMed ID: 22019345
[TBL] [Abstract][Full Text] [Related]
3. Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials.
Allgulander C; Hartford J; Russell J; Ball S; Erickson J; Raskin J; Rynn M
Curr Med Res Opin; 2007 Jun; 23(6):1245-52. PubMed ID: 17559726
[TBL] [Abstract][Full Text] [Related]
4. Duloxetine versus placebo in the treatment of patients with generalized anxiety disorder in China.
Wu WY; Wang G; Ball SG; Desaiah D; Ang QQ
Chin Med J (Engl); 2011 Oct; 124(20):3260-8. PubMed ID: 22088518
[TBL] [Abstract][Full Text] [Related]
5. Visual hallucinations during duloxetine treatment in a patient with major depressive disorder.
Tomita T; Yasui-Furukori N; Kaneko S
Clin Neuropharmacol; 2013; 36(5):175-6. PubMed ID: 24045610
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with duloxetine treatment among patients with major depressive disorder in Veterans Health Administration: a retrospective study.
Shi L; Liu J; Campbell C; Zhao Y
Curr Med Res Opin; 2010 Dec; 26(12):2715-21. PubMed ID: 20973616
[TBL] [Abstract][Full Text] [Related]
8. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
Arnold LM; Lu Y; Crofford LJ; Wohlreich M; Detke MJ; Iyengar S; Goldstein DJ
Arthritis Rheum; 2004 Sep; 50(9):2974-84. PubMed ID: 15457467
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial.
Rynn M; Russell J; Erickson J; Detke MJ; Ball S; Dinkel J; Rickels K; Raskin J
Depress Anxiety; 2008; 25(3):182-9. PubMed ID: 17311303
[TBL] [Abstract][Full Text] [Related]
10. Duloxetine in the treatment of major psychiatric and neuropathic disorders.
Müller N; Schennach R; Riedel M; Möller HJ
Expert Rev Neurother; 2008 Apr; 8(4):527-36. PubMed ID: 18416656
[TBL] [Abstract][Full Text] [Related]
11. Predictors of relapse in a study of duloxetine treatment in patients with major depressive disorder.
Fava M; Wiltse C; Walker D; Brecht S; Chen A; Perahia D
J Affect Disord; 2009 Mar; 113(3):263-71. PubMed ID: 18625521
[TBL] [Abstract][Full Text] [Related]
12. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
13. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
[TBL] [Abstract][Full Text] [Related]
14. Trajectory analysis of healthcare costs for patients with major depressive disorder treated with high doses of duloxetine.
Cui Z; Faries DE; Zhao Y; Novick D; Liu X
J Med Econ; 2011; 14(5):662-72. PubMed ID: 21892857
[TBL] [Abstract][Full Text] [Related]
15. Duloxetine for major depressive disorder and daytime and nighttime hot flashes associated with the menopausal transition.
Freeman MP; Hirschberg AM; Wang B; Petrillo LF; Connors S; Regan S; Joffe H; Cohen LS
Maturitas; 2013 Jun; 75(2):170-4. PubMed ID: 23602542
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms.
Russell JM; Weisberg R; Fava M; Hartford JT; Erickson JS; D'Souza DN
Depress Anxiety; 2008; 25(7):E1-11. PubMed ID: 17587217
[TBL] [Abstract][Full Text] [Related]
17. Duloxetine in the acute and continuation treatment of major depressive disorder.
Bochsler L; Olver JS; Norman TR
Expert Rev Neurother; 2011 Nov; 11(11):1525-39. PubMed ID: 22014130
[TBL] [Abstract][Full Text] [Related]
18. A retrospective pooled analysis of duloxetine safety in 23,983 subjects.
Gahimer J; Wernicke J; Yalcin I; Ossanna MJ; Wulster-Radcliffe M; Viktrup L
Curr Med Res Opin; 2007 Jan; 23(1):175-84. PubMed ID: 17257478
[TBL] [Abstract][Full Text] [Related]
19. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
[TBL] [Abstract][Full Text] [Related]
20. Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials.
Nelson JC
Depress Anxiety; 2010; 27(1):12-8. PubMed ID: 20013987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
